SORAMIC is the first large randomised controlled trial (RCT) to compare the efficacy and safety of combining sorafenib and SIR-Spheres® Y-90 resin microspheres versus sorafenib alone in the treatment of HCC in the palliative cohort. Patients with HCC who took part in the palliative cohort of the SORAMIC study were not eligible for resection or ablation, and were not ideal candidates for transarterial chemoembolisation (TACE).

The primary endpoint of the palliative arm of the SORAMIC study is Overall Survival (OS). Secondary endpoints include Safety and OS for patients with and without portal vein thrombosis.

Results of the SORAMIC study are expected in 2018.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage